Panacea Biotec Ltd
Panacea Biotec Ltd (PANACEABIO) last reported results for the quarter ended Jun 2026, with sales of ₹200 crore and net profit of ₹2.2 crore. The stock last traded at ₹357, a market capitalisation of ₹2,185 crore. Over the past 52 weeks the stock has ranged between ₹292 and ₹648. Figures are as of 6 Oct 2026 and are not real time.
Panacea Biotec Ltd share price and key metrics
- Current price
- ₹357
- Market cap
- ₹2,185 cr
- Book value
- ₹136
- ROE
- -2.42%
- ROCE
- -2.43%
- Dividend yield
- 0.00%
- 52w high / low
- 648/292
Metrics as of 6 Oct 2026. Not real time.
Track Panacea Biotec Ltd
Cruxal reads every Panacea Biotec Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Panacea Biotec Ltd growth and returns
- 10 Years
- 0%
- 5 Years
- 0%
- 3 Years
- 12%
- TTM
- 10%
- 10 Years
- 5%
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- 43%
- 10 Years
- 13%
- 5 Years
- 5%
- 3 Years
- 26%
- 1 Year
- -18%
- 10 Years
- %
- 5 Years
- -10%
- 3 Years
- -4%
- Last Year
- -2%
Panacea Biotec Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹200 cr, up 19.7% from ₹167 cr a year earlier. Net profit was ₹2.2 cr, down 44.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Expenses | 140 | 156 | 159 | 168 | 159 | 153 | 164 | 194 |
| Operating profit | 7 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 |
| OPM % | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% |
| Other income | 7.42 | 6.39 | 36.3 | 16.99 | 9.1 | 5.05 | 5.26 | 6.98 |
| Interest | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.2 | 1.18 |
| Depreciation | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | 7.9 |
| Profit before tax | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 |
| Tax % | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | 38.38% |
| Net profit | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1 | 2.2 |
| EPS (₹) | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Panacea Biotec Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 | 673 |
| Operating profit | 39 | 84 | -134 | 60 | 77 | -13 | -98 | -20 | -25 | -5 | 2 |
| OPM % | 7% | 14% | -29% | 11% | 12% | -2.0% | -21% | -3.5% | -4.4% | -0.7% | 0.3% |
| Net profit | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | -7 | -9 |
| EPS (₹) | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | -0.88 | -1.16 |
TTM is the trailing twelve months to the most recent quarter.
Panacea Biotec Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 | 829 |
| Borrowings | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 | 24 |
| Other liabilities | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 | 404 |
| Total liabilities | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,262 |
| Fixed assets | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 567 | 576 |
| CWIP | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 128 | 144 |
| Investments | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 | 10 |
| Other assets | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 | 532 |
| Total assets | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,262 |
As reported by the company. Total assets equal total liabilities by construction.
Panacea Biotec Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 131 | 118 | 105 | -30 | 107 | -108 | -422 | -0 | -27 | 17 |
| Cash from investing | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | 10 | 65 | -40 |
| Cash from financing | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 | -1 |
| Net cash flow | -2 | 9 | -2 | 26 | 12 | -2 | -10 | 7 | 35 | -25 |
| Free cash flow | 107 | 103 | 100 | -21 | 89 | -119 | -424 | -71 | -77 | -37 |
| CFO / operating profit | 320% | 146% | -77% | -36% | 141% | -2,235% | 429% | -12% | 108% | -511% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Panacea Biotec Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 2% | 3% | -16% | 5% | 5% | -6% | -10% | -4% | -5% | -2% |
| Debtor days | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 | 42 |
| Inventory days | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 | 251 |
| Days payable | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 | 247 |
| Cash conversion cycle | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 | 46 |
| Working capital days | -46 | -96 | -363 | 93 | -43 | -229 | -5 | -2 | 65 | 51 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Panacea Biotec Ltd shareholding pattern
Promoters held 72.48% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.31% and DIIs 2.25%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.87% | 72.49% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% |
| FIIs | 0.37% | 0.38% | 1.16% | 0.79% | 1.06% | 1.36% | 1.60% | 2.31% |
| DIIs | 1.16% | 1.16% | 1.49% | 1.52% | 1.80% | 1.85% | 1.96% | 2.25% |
| Public | 25.60% | 25.96% | 24.86% | 25.20% | 24.65% | 24.31% | 23.96% | 22.96% |
| No. of shareholders | 39,982 | 35,446 | 33,593 | 34,256 | 33,593 | 34,597 | 32,620 | 33,532 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Panacea Biotec Ltd corporate filings
- Panacea Biotec announces publication of notice for opening of special window for transfer and dematerialisation of physical sharesCompany Updatelow impact
Cruxal's analysis: The company has published notices in newspapers regarding the opening of a special window…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached certificate dated October 01, 2026 issued by Skyline Financial…
Read the full analysis - Shares Dematerialized During September 2026 Reported for Panacea Biotec LtdCompany Updatelow impact
Cruxal's analysis: Panacea Biotec Ltd has filed details of shares dematerialized in September 2026 under…
Read the full analysis - Panacea Biotec Passes Shareholder Resolutions with Over 99.9% Approval via E-votingAGM/EGMlow impact
Cruxal's analysis: Panacea Biotec Limited has successfully obtained shareholder approval for all key…
Read the full analysis - Panacea Biotec's AGM confirms ongoing strategic focus amid mixed financials; key resolutions include re-appointments and appointment of independent director, with upcoming voting results expected by October 1, 2026AGM/EGMmedium impact
Cruxal's analysis: Panacea Biotec Limited held its 42nd AGM on September 29, 2026 via video conferencing…
Read the full analysis - We would like to inform you that the Company has received 2 Demand Orders dated 28.09.2026, from the Office of the Assistant Commissioner of Income Tax, Delhi imposing penalty on account ....Company Updatemedium impact
- Panacea Biotec receives income tax penalty orders aggregating 9 crore 82 lakh INRCompany Updatemedium impact
Cruxal's analysis: Panacea Biotec Limited has disclosed the receipt of four demand orders from the Income…
Read the full analysis - The trading window of the Company shall remain closed for all the Designated Persons (including their immediate relatives) of the Company from October 01, 2026 till completion of 48 hours ....Insider Trading / SASTlow impact
- Panacea Biotec issues reminder to physical shareholders for PAN and KYC updationCompany Updatelow impact
Cruxal's analysis: Panacea Biotec has issued reminder letters dated 15.09.2026 to shareholders holding…
Read the full analysis - Panacea Biotec Limited Announces 42nd Annual General Meeting and E-Voting ScheduleCompany Updatelow impact
Cruxal's analysis: Panacea Biotec Limited has issued a formal notice for its 42nd Annual General Meeting…
Read the full analysis - Panacea Biotec Ltd announces book closure for Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Panacea Biotec Ltd has issued an intimation regarding the book closure for its upcoming…
Read the full analysis - Panacea Biotec Limited schedules 42nd Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Panacea Biotec Limited has issued a formal notice for its 42nd Annual General Meeting…
Read the full analysis - Panacea Biotec Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Panacea Biotec has submitted its Business Responsibility and Sustainability Report (BRSR)…
Read the full analysis - Panacea Biotec Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Panacea Biotec has filed its Annual Report for the financial year 2025-26. The disclosure…
Read the full analysis - Panacea Biotec Announces 42nd Annual General Meeting and Appointment of Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Panacea Biotec Limited has scheduled its 42nd Annual General Meeting (AGM) for September…
Read the full analysis - Panacea Biotec Ltd: Disclosure of shares dematerialized for August 2026Company Updatelow impact
Cruxal's analysis: Panacea Biotec Ltd has filed a routine compliance report under Regulation 74(5) of the…
Read the full analysis - Panacea Biotec Limited schedules 42nd Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Panacea Biotec Limited has issued a public notice regarding its 42nd Annual General…
Read the full analysis - Panacea Biotec Reports Q1 FY2027 Financial Results with Net Profit of 2.20 croreCompany Updatemedium impact
Cruxal's analysis: Panacea Biotec Limited has released its unaudited standalone and consolidated financial…
Read the full analysis - Panacea Biotec Reports Q1 FY27 Turnaround with Consolidated Net Profit of 2.20 croreBoard Meetinghigh impact
Cruxal's analysis: Panacea Biotec Limited has reported a return to profitability for the quarter ended June…
Read the full analysis - Panacea Biotec Ltd announces special window for physical share dematerializationCompany Updatelow impact
Cruxal's analysis: Panacea Biotec has published a newspaper notice informing shareholders about the opening…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.